All In Biotech

NDA 214094 · Biocryst

Orladeyo

Berotralstat Dihydrochloride · Oral

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Dec 3, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

0

0 Phase 3, 0 recruiting

FAERS reports

911

434 serious, 28 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 23, 2026.

ORLADEYO ® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years of age and older. ORLADEYO is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years and older. ( 1 ) Limitations of Use : ORLADEYO should not be used for treatment of acute HAE attacks. ( 1 ) Limitations of Use : The safety and effectiveness of ORLADEYO for the treatment of acute HAE attacks have not been established. ORLADEYO should not be used for treatment of acute HAE attacks. Additional doses or doses of ORLADEYO higher than the prescribed once-daily dose are not recommended due to the potential for QTc interval prolongation [see Warnings and Precautions (5.1) ] .

Mechanism: Berotralstat is a plasma kallikrein inhibitor that binds to plasma kallikrein and inhibits its proteolytic activity. Plasma kallikrein is a protease that cleaves high-molecular-weight kininogen (HMWK) to generate cleaved HMWK (cHMWK) and bradykinin, a potent vasodilator that increases vascular permeability resulting in swelling and pain associated with HAE. In patients with HAE due to C1-inhibitor (C1-INH) deficiency or dysfunction, normal regulation of plasma kallikrein activity is not present, which leads to uncontrolled increases in plasma kallikrein activity and results in angioedema...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 3, 2020 Original approval · Type 1 - New Molecular Entity NovelOrphanLetterLabelReview
2 products under this application
  • ORLADEYO · BEROTRALSTAT DIHYDROCHLORIDE EQ 150MG BASE · CAPSULE, ORAL · Prescription
  • ORLADEYO · BEROTRALSTAT DIHYDROCHLORIDE EQ 110MG BASE · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Berotralstat Dihydrochloride" as an intervention, any sponsor and status, largest first.

All 0 trials

No registered drug trials name this ingredient.

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hereditary angioedema258
  • nausea63
  • diarrhoea62
  • drug ineffective61
  • headache56
  • abdominal pain52
  • gastrointestinal disorder50
  • condition aggravated47
  • fatigue44
  • vomiting40
  • malaise37
  • abdominal pain upper36

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20191
20205
202170
202286
2023105
2024201
2025308
2026135

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Orladeyo (Berotralstat Hydrochloride)

2024 spending

$77.9M

Beneficiaries

221

1,835 claims

Per beneficiary

$352,465

$1,516.05 per unit

View as table
YearSpending
2020$0
2021$26,481,757
2022$47,943,573
2023$52,329,473
2024$77,894,703

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Biocryst

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.